Navigation Links
InfuSystem Pays Down Term Loan by $6.1 Million Year-to-Date
Date:4/8/2009

MADISON HEIGHTS, Mich., April 8 /PRNewswire-FirstCall/ -- InfuSystem (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it has made a $5.3 million payment on its Term Loan in addition to its normal quarterly $818,000 payment. As a result of the combined payments year-to-date, InfuSystem has reduced the total amount outstanding on its Term Loan by $6.1 million, to $24.1 million. The Term Loan was a result of the sale of InfuSystem, Inc. from its former parent company, completed in October 2007.

Mr. Steve Watkins, Chief Executive Officer, commented, "InfuSystem continues to generate strong free cash flow, which has enabled us to rapidly pay down our Term Loan. The Term Loan originally stood at $32.7 million as of October 2007, and in less than 18 months, we have reduced the principal amount due by over $8.5 million. We plan to continue aggressively paying down this loan, while maintaining a solid cash position on our balance sheet."

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.


'/>"/>
SOURCE InfuSystem Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InfuSystem Holdings Reports 12.9% Revenue Increase and $3.3 Million of Adjusted EBITDA for the Fourth Quarter of 2008
2. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
3. InfuSystem Holdings Appoints Two New Board Members
4. ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing
5. Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
6. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
7. Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses
8. The Healy Law Firm Represents Plaintiff in $12 Million Settlement with Clark USA Over Fatal Illinois Oil Refinery Accident
9. Siemens Financial Services, Inc. Provides $29.5 Million Credit Package to Avanti Health System
10. Partnership for Prescription Assistance Celebrates Four-Year Anniversary; Helps More Than 5.7 Million Uninsured Patients Across United States
11. Harris Corporation Awarded $14 Million Contract to Develop Multi-Hospital Military Health System Network with Image-Sharing Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
Breaking Medicine Technology: